All Updates

All Updates

icon
Filter
Partnerships
Sangamo Therapeutics and Genentech partner to develop genomic medicines for neurodegenerative disorders
Longevity Tech
Aug 6, 2024
This week:
Management news
6K Additive awarded project to develop C-103 powder for additive manufacturing
Additive Manufacturing
Sep 27, 2024
Partnerships
WAAM3D partners with Innovative Space Carrier, Cranfield University, and Aichi Sangyo for space transport development
Additive Manufacturing
Sep 19, 2024
Product updates
Akselos introduces software for FPSO monitoring
Digital Twin
Yesterday
Funding
Operant AI raises USD 10 million in Series A funding to boost runtime protection
Next-gen Cybersecurity
Yesterday
Funding
Aembit raises USD 25 million in Series A funding to advance IAM solutions
Identity & Access Management
Yesterday
Product updates
Saviynt launches Intelligence Suite for identity security
Identity & Access Management
Yesterday
Partnerships
Geographic expansion
FarmWise partners with RDO Equipment Co. to expand AI-powered weeding technology for vegetable growers
Smart Farming
Yesterday
Management news
Alberta Food Security Inc. receives USD 5 million order for indoor farming technology
Vertical Farming
Yesterday
Partnerships
AutoStore enhances microfulfilment offering with new grid capabilities and multi-temperature solution
Logistics Tech
Yesterday
Product updates
OpenAI launches o1, a self-fact-checking AI model
Generative AI Applications
Yesterday
Longevity Tech

Longevity Tech

Aug 6, 2024

Sangamo Therapeutics and Genentech partner to develop genomic medicines for neurodegenerative disorders

Partnerships

  • Sangamo Therapeutics has entered a global licensing agreement with Genentech to advance the development of intravenous genomic medicines targeting neurodegenerative disorders. 

  • According to the agreement, Genentech willpay Sangamo USD 50 million in upfront license fees and near-term milestone payments. Additionally, Sangamo could receive up to USD 1.9 billion upon achieving development and commercial milestones, as well as tiered royalties based on net sales of the products.

  • Through this partnership, Sangamo will grant Genentech exclusive licenses to its zinc finger repressors which target the Alzheimer's-related tau gene and another undisclosed neurological target, alongside Sangamo's proprietary AAV capsid, STAC-BBB, recognized for its effective blood-brain barrier penetration. Sangamo will manage transfer and preclinical tasks, whereas Genentech will lead clinical development, regulatory affairs, manufacturing, and commercialization.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.